Tag Archives: asthma

GSK to Showcase Transformative Respiratory Research at ERS Congress 2024

(IN BRIEF) GSK will present significant research at the 2024 European Respiratory Society (ERS) Congress, including data from phase III trials of its new biologic, depemokimab, for severe asthma. The presentations highlight GSK’s commitment to advancing respiratory medicine, with a … Read the full press release

Early Teenage Smoking in Boys Linked to Health Risks in Future Children, Reveals University of Southampton Study

(IN BRIEF) A recent study conducted by researchers from the University of Southampton and the University of Bergen reveals that boys who smoke during their early teenage years are at risk of damaging the genes of their future children. The … Read the full press release

Study identifies risk factors associated with long Covid

(IN BRIEF) New research from the University of East Anglia has found that being vaccinated against Covid-19 can halve the risk of developing long Covid. The study, which is the largest of its kind and includes more than 860,000 patients, … Read the full press release

AstraZeneca’s Tezspire receives EU approval for self-administration in a convenient pre-filled pen for severe asthma patients

(PRESS RELEASE) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced that its drug Tezspire (tezepelumab) has been given the green light for self-administration by the European Medicine Agency’s Committee for Medicinal … Read the full press release

Zweite Phase-3-Studie für Dupixent/Dupilumab: Das Medikament kann Juckreiz und Hautläsionen bei Patienten mit unkontrollierter Prurigo nodularis deutlich reduzieren

Dupixent ist das erste und einzige Medikament mit positiven Phase-3-Ergebnissen bei Prurigo nodularis, was den potenziellen Nutzen einer gezielten Behandlung von IL-4 und IL-13, zentralen Treibern von Typ-2-Entzündungen, zur Behandlung von Juckreiz und Hautläsionen bestätigt Die Daten bestätigen die Ergebnisse … Read the full press release

Second Phase 3 trial for Dupixent/Dupilumab: the medicine can significantly reduce itch and skin lesions in patients with uncontrolled prurigo nodularis

Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions Data confirm results … Read the full press release

Aimmune Therapeutics now a Nestlé Health Science company

(PRESS RELEASE) VEVEY, 14-Oct-2020 — /EuropaWire/ — Nestlé has successfully closed the acquisition of biopharmaceutical company, Aimmune Therapeutics, Inc. (Nasdaq: AIMT). The company which specializes in developing and bringing new treatments to people with potentially life-threatening food allergies joins Nestlé … Read the full press release

AstraZeneca enters into an agreement with Covis Pharma to sell its rights to Alvesco, Omnaris and Zetonna

CAMBRIDGE, 07-Nov-2018 — /EuropaWire/ — AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with … Read the full press release

AstraZeneca and Amgen announce US FDA Breakthrough Therapy Designation for tezepelumab in patients with severe asthma

AstraZeneca’s first Breakthrough Therapy Designation for a respiratory medicine Designation based on Phase IIb PATHWAY data that demonstrated tezepelumab significantly reduced asthma exacerbations compared to placebo in severe asthma CAMBRIDGE, 12-Sep-2018 — /EuropaWire/ — AstraZeneca and its partner Amgen Inc. (Amgen) … Read the full press release

Dupixent demonstrated significant improvement in multiple asthma endpoints in two Phase 3 clinical trials

Results showed Dupixent demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials in a broad population of patients with uncontrolled asthma, irrespective of minimum baseline eosinophil levels or other biomarkers of Type 2 inflammation Greater … Read the full press release

GlaxoSmithKline to present comprehensive portfolio of respiratory research and scientific innovation at the American Thoracic Society (ATS) conference

Brentford, United Kingdom, 17-May-2018 — /EuropaWire/ — GlaxoSmithKline plc (GSK) will present extensive data from across its respiratory portfolio, pipeline and early phase research programmes at the American Thoracic Society (ATS) conference in San Diego, USA, 19-23 May 2018. Data presented … Read the full press release

Royal Philips to help parents take charge of their children’s asthma and allergy symptoms through awareness initiatives in more than 20 countries worldwide

Company opens new pollen measurement station at its Drachten innovation center in the Netherlands AMSTERDAM, 26-Apr-2018 — /EuropaWire/ — This World Allergy Week (April 22 – 28) and World Asthma Day (May 1), Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in … Read the full press release

Study: 38% of all annual childhood asthma cases in Bradford may be caused by air pollution

LEEDS, 02-Apr-2018 — /EuropaWire/ — New research suggests that up to 38% of all annual childhood asthma cases in Bradford may be caused by air pollution. The study, led by the University of Leeds, also shows traffic-related air pollution could be … Read the full press release

Accredited Symptomatic Asthma CME Launched on epgonline.org

Not for audiences in the US and Canada LONDON, 26-8-2015 — /EuropaWire/ — This week, epgonline.org, the website for healthcare professionals, welcomes the launch of a free symptomatic asthma Continuing Medical Education (CME) activity, available at epgonline.org/symptomatic-asthma/cme/. Accredited by the … Read the full press release

With air pollution in Paris and London hitting Beijing and Delhi levels, Blueair warns indoor air can bring its own health hazards

Stockholm, Sweden, 24-3-2015 — /EuropaWire/ — Blueair, the world’s leading mobile indoor air purifying technologies company, Monday warned that indoor air in homes and offices can be many times more polluted than the air outside. Commenting on the recent severe smog … Read the full press release

Clean indoor air to get excited about at Berlin’s IFA 2014 gadget show

LONDON, 6-8-2014 — /EuropaWire/ — Berlin’s annual IFA tech expo opens to the public on September 5 and this year global indoor air cleaning technology company Blueair unveils new ultra high performance technologies to clean the air of practically all … Read the full press release

Sandoz announced it received Romanian marketing authorization for AirFluSal® Forspiro®

Holzkirchen, Germany, 31-1-2014 — /EuropaWire/ — Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD. The product was first approved in Denmark on December 18th, 2013. The new product … Read the full press release

GlaxoSmithKline submitted NDA to US FDA for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA™ dry powder inhaler

London, UK, 23-10-2013 — /EuropaWire/ — GlaxoSmithKline plc (LSE:GSK) today announced the submission of a New Drug Application (NDA) in the US for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA™ dry powder inhaler. The NDA … Read the full press release

University of Leicester health research led by Professor Kamlesh Khunti received £28.4M funding to speed up impact for patients across East Midlands

12-8-2013 — /EuropaWire/ — Research led by University of Leicester health expert aims to speed up impact for patients across the region Issued by Nottinghamshire Heathcare NHS Trust on 9 August 2013 A collaboration between the NHS and universities across the … Read the full press release